Relief Therapeutics Reports Promising Outcomes from PKU GOLIKE Trial

Relief Therapeutics Holding SA has announced the successful completion of a clinical trial for PKU GOLIKE®, a protein substitute for phenylketonuria (PKU) patients. The study revealed improved metabolic control during prolonged fasting, specifically lowering phenylalanine levels and increasing tyrosine levels, which are crucial for brain and metabolic health. Conducted at Birmingham Children’s Hospital, the study involved pediatric patients with classical PKU, comparing PKU GOLIKE to standard protein substitutes during overnight fasting.

Results indicated a significant 17.8% reduction in blood phenylalanine and a 33.8% increase in tyrosine levels for patients taking PKU GOLIKE. In contrast, those using standard substitutes saw a 27.6% increase in phenylalanine levels and no notable change in tyrosine. Relief anticipates these findings will enhance awareness and promote the adoption of PKU GOLIKE in medical practice.

The study findings will be shared at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles. For further details, see clinical trial NCT05487378.